Peptide Therapy Cost in 2026: What Telehealth Clinics Charge for BPC-157, Sermorelin, and GLP-1s
Peptide therapy cost in 2026 — monthly pricing for BPC-157, sermorelin, semaglutide, tirzepatide, and GHK-Cu across telehealth clinics, compounding pharmacies, and gray-market sources, with HSA/FSA eligibility and annual projections.
In Q4 2024, a 30-day supply of compounded semaglutide from one of the major telehealth clinics — Mochi, Henry Meds, Hims Weight Loss — ran $199–$299 per month. By Q3 2025, that supply chain had largely collapsed. The FDA's February 2025 declaration that the semaglutide shortage was resolved triggered the wind-down of routine 503A compounding for semaglutide; the October 2024 tirzepatide declaration had done the same for compounded tirzepatide six months earlier. Patients who had been paying $299/month for compounded semaglutide moved to $1,329/month for branded Wegovy if they could afford it, or off the medication entirely if they could not.
The April 2024 FDA Category 2 placement of BPC-157, ipamorelin, AOD-9604, CJC-1295, epitalon, and thymosin beta-4 produced a parallel disruption in the recovery and longevity peptide market. Telehealth clinics offering these peptides either narrowed their offerings, pivoted to research-chemical-style sales, or shut down peptide programs entirely. Pricing in 2026 reflects this regulatory churn.
This is the actual cost picture in 2026 — telehealth markups, compounding pharmacy direct pricing, gray-market research chemical ranges, and the insurance and HSA/FSA realities that determine effective out-of-pocket cost.
The Three Pricing Channels
Peptide pricing varies by sourcing channel, and the channels operate under different regulatory and quality control frameworks. The legal status framework is detailed in the peptide legality picture; the cost implications follow from that framework.
Channel 1: Telehealth clinics. Includes Hone Health, Marek Health, Eden, Henry Meds, Mochi, Push Health, and dozens of smaller operations. Pricing bundles physician consultation, prescription, compounded medication, shipping, and customer service. Markup over underlying medication cost is typically 50–150%. The model worked well during the GLP-1 compounding window; it has narrowed substantially since the 2024–2025 regulatory shifts.
Channel 2: Compounding pharmacies direct. Empower Pharmacy, Strive Pharmacy, Tailor Made Compounding, Olympia Pharmaceuticals, and other 503A and 503B operations. Requires a prescription from a licensed physician, but the patient interfaces with the pharmacy directly rather than through a clinic intermediary. Pricing is the underlying compounded cost without clinic markup. Typical savings 30–60% vs telehealth-equivalent products.
Channel 3: Gray-market research chemicals. Peptide Sciences, Polaris, Limitless Life, Pure Peptides, and many others. Operating under "for research use only, not for human consumption" labeling. No prescription required. No physician oversight. Quality varies by supplier from pharmaceutical-grade to substantially lower. Pricing is the cheapest of the three channels by a wide margin — typically 40–70% below compounding pharmacy direct, 60–80% below telehealth clinic equivalent.
The cost-quality-legality trade-offs are real. Channel 1 provides the cleanest medical-legal framework at the highest price point. Channel 3 provides the lowest price point at the highest legal and quality control risk. Channel 2 is the middle path that requires an existing relationship with a prescriber willing to write to a compounding pharmacy.
BPC-157: Cost by Channel
BPC-157 is the prototypical recovery peptide and the most common starting point for peptide cost questions. The 2026 pricing landscape:
Telehealth clinics: $250–450 per month for protocols at 250–500 mcg daily. Some clinics removed BPC-157 from offerings after the April 2024 Category 2 placement; others continue under specialized clinical justifications at higher prices. The market is fragmented and changing.
Compounding pharmacy direct: $150–280 per month for the same protocol, where the prescriber-pharmacy relationship still permits Category 2 compounding. Variable by state and pharmacy.
Gray-market research chemicals: $80–150 per month for the same protocol. A 5 mg vial costs $40–80 from major suppliers; a 250 mcg daily protocol uses one vial per ~20 days, so $60–120 per month depending on dose. The reconstitution practical guide walks through the dosing math.
Annual projection at typical dosing:
- Telehealth: $3,000–5,400
- Compounding direct: $1,800–3,360
- Gray-market: $1,000–1,800
The healing peptides evidence map covers when BPC-157 is the right intervention; the cost picture is what determines whether the right intervention is accessible. For many users, gray-market sourcing is the only viable cost structure for chronic use.
Sermorelin and Growth Hormone Secretagogues
Sermorelin is a GHRH analog that stimulates endogenous growth hormone release. Combined with GHRPs like ipamorelin or hexarelin, the protocol amplifies GH pulse frequency. Pricing:
Sermorelin alone, telehealth clinics: $200–350 per month at typical doses of 200–300 mcg before sleep. Hone, Marek, and similar clinics commonly offer sermorelin protocols at this price point. The branded versions of sermorelin (Geref, Sermorelin Acetate) are discontinued; current supply is exclusively compounded.
Sermorelin/ipamorelin combination, telehealth clinics: $300–500 per month. Adds the GHRP for amplified GH pulse. Common stack for body composition and recovery applications.
Compounding pharmacy direct: $120–220 per month for sermorelin alone; $180–320 per month for combinations. Substantial savings over telehealth.
Gray-market: $60–140 per month for sermorelin or sermorelin/ipamorelin combinations at typical doses. Research chemical pricing for GHRH analogs and GHRPs is among the lowest in the peptide market.
Annual projection at typical dosing:
- Telehealth (combination): $3,600–6,000
- Compounding direct (combination): $2,160–3,840
- Gray-market: $720–1,680
Ipamorelin specifically is in Category 2 status alongside BPC-157 — compounding pharmacy access has narrowed since April 2024. Sermorelin itself was not placed in Category 2 and remains more accessible through compounding.
The men's peptide overview covers GHRH/GHRP protocols in clinical context.
GLP-1 Receptor Agonists: The Post-Shutdown Pricing
The compounded GLP-1 era ended in 2025. The 2026 pricing landscape:
Branded Wegovy (semaglutide 2.4 mg): $1,329 per month retail cash. Insurance coverage variable — approximately 60% of commercial plans cover with prior authorization for BMI ≥30 or ≥27 with comorbidity. Medicare does not cover for weight loss; covers Ozempic for diabetes. Effective out-of-pocket with insurance approval often $25–150/month copay; without insurance approval $1,329/month or coupon-discounted $1,029/month.
Branded Zepbound (tirzepatide): $1,059–1,394 per month retail cash depending on dose. Eli Lilly's LillyDirect program offers single-dose vials at $349–499/month for cash-pay patients, narrowing the cash-pay vs insured gap.
Branded Ozempic (semaglutide 1.0 mg): $968 per month retail. Covered by most commercial insurance for type 2 diabetes; off-label use for obesity often denied. The off-label dose for obesity typically exceeds the labeled diabetes dose, complicating coverage.
Branded Mounjaro (tirzepatide for diabetes): $1,069 per month retail. Similar coverage pattern to Ozempic.
Compounded semaglutide (where available): $200–450 per month. Substantially more expensive than the 2023–2024 era's $199–299 pricing but still well below branded. Access is restricted to patient-specific clinical justifications post-shortage delisting.
Compounded tirzepatide (where available): $350–700 per month. Similar access restrictions.
Gray-market semaglutide and tirzepatide: $80–250 per month at typical doses. Substantially cheaper but operating in higher legal and quality risk. Sourcing through international suppliers has increased as US compounded supply contracted.
Annual projection at typical maintenance dosing:
- Branded Wegovy with insurance approval: $300–1,800 in copays
- Branded Wegovy cash-pay: $15,948
- Branded Zepbound LillyDirect cash-pay: $4,188–5,988
- Compounded semaglutide (where available): $2,400–5,400
- Gray-market: $960–3,000
The tirzepatide mechanism deep-dive, retatrutide picture, and cagrilintide picture cover the clinical context; cost is what determines whether the clinical option is accessible.
PT-141 (Bremelanotide)
PT-141 pricing differs from chronic peptide protocols because the standard use is situational rather than daily.
Branded Vyleesi (1.75 mg autoinjector): $987 for a 4-pack (4 doses) — approximately $247 per dose. FDA-approved for HSDD in premenopausal women; male use is off-label and typically not insurance-covered.
Telehealth clinics: $200–400 per month for PT-141 protocols including 2–4 typical doses. Hone, Eden, and several smaller clinics offer compounded PT-141 in 10 mg vials with usage guidance for off-label male ED and libido protocols.
Compounding pharmacy direct: $120–250 per month for similar volume. PT-141 is not in Category 2; compounding access is more stable than for BPC-157 or ipamorelin.
Gray-market: $40–90 per 10 mg vial. At 1–2 mg per dose, a 10 mg vial provides 5–10 doses, so per-dose cost is $4–18. Monthly cost depends entirely on usage frequency.
The PT-141 for libido picture and PT-141 vs sildenafil for ED comparison cover the clinical decision-making.
GHK-Cu, KPV, and Other Recovery Peptides
The smaller peptides relevant to recovery, skin health, and inflammation protocols have similar channel-based pricing structures.
GHK-Cu (copper peptide):
- Telehealth: $180–350 per month
- Compounding direct: $100–220 per month
- Gray-market: $40–100 per month (50 mg vials at $40–80, dosed at 1–2 mg)
The GHK-Cu therapeutic picture covers the clinical applications.
KPV (lysine-proline-valine fragment of α-MSH):
- Telehealth: $200–380 per month
- Compounding direct: $120–240 per month
- Gray-market: $60–120 per month
The KPV anti-inflammatory profile covers the clinical use.
Thymosin Alpha-1 (TA-1):
- Telehealth: $250–450 per month
- Compounding direct: $150–280 per month
- Gray-market: $80–160 per month
KLOW stack (KPV + Larazotide + Omeprazole/Pancreatin + Wormwood-style components, varies by formulation):
- Telehealth: $350–550 per month (often only via specialized clinics)
- Compounding direct: $220–380 per month
- Gray-market: less common as a pre-mixed stack; individual components $150–280 per month combined
The KLOW peptide stack picture covers the gut-focused protocol.
The compounded GLP-1 era was an arbitrage window between shortage and supply. It closed in 2025. The 2026 cost picture is what peptide therapy actually costs when the regulatory framework is back in normal operation.
AOD-9604, Tesofensine, and Fat-Loss Adjuncts
The fat-loss peptide market has expanded as alternatives to GLP-1 receptor agonists.
AOD-9604: $150–280 per month telehealth; $80–180 compounding direct; $40–100 gray-market. The AOD-9604 fat loss picture covers the mechanism — modified GH fragment without the GH side effects.
Tesofensine: $250–450 per month telehealth where available; less common compounding pathway; $80–200 gray-market. The tesofensine fat loss picture covers the noradrenergic/dopaminergic mechanism distinct from GLP-1 class.
Cognition Peptides
Dihexa: $180–380 per month telehealth; $100–220 compounding direct; $60–140 gray-market. The dihexa cognition profile covers the HGF/c-Met mechanism.
Semax (intranasal): $120–260 per month telehealth; $80–160 compounding direct; $40–100 gray-market. The semax overview covers the BDNF mechanism.
Selank (intranasal): $130–270 per month telehealth; $90–180 compounding direct; $50–110 gray-market. The selank anxiety profile covers the GABA-modulatory mechanism.
SS-31 and Mitochondrial Peptides
SS-31 (elamipretide) is positioned differently — it has been in clinical development with several pharmaceutical companies and exists primarily in research and limited compounded supply rather than retail pricing structures.
Telehealth clinics: $400–750 per month where available; most clinics do not offer SS-31. Compounding direct: $250–500 per month. Gray-market: $150–300 per month.
The SS-31 mitochondrial profile covers the clinical context.
Wolverine Stack and Combination Protocols
The Wolverine peptide stack protocol combines BPC-157, TB-500, and GHK-Cu for amplified recovery effects. Stack pricing:
Telehealth: $600–1,000 per month for the full stack Compounding direct: $380–650 per month Gray-market: $180–380 per month
Annual stack cost ranges $2,160–12,000 depending on channel — the widest spread among common peptide protocols.
HSA/FSA Eligibility and Insurance Realities
The reimbursement landscape:
FDA-approved peptide drugs prescribed for label indications: full HSA/FSA eligibility, insurance coverage variable but possible. Wegovy and Zepbound for obesity with documented BMI criteria are typical examples. Ozempic and Mounjaro for diabetes are routinely covered.
FDA-approved peptide drugs prescribed off-label: HSA/FSA eligibility usually requires Letter of Medical Necessity. Insurance coverage commonly denied. PT-141 off-label male use is a typical example — HSA/FSA may approve with LMN; insurance typically denies.
Compounded peptides with physician prescription: HSA/FSA eligibility variable. Some plan administrators accept compounded medications with prescription documentation; others require explicit FDA-approval status. LMN documentation helps. Insurance coverage almost universally denied.
Research chemical peptides: never HSA/FSA-eligible because they are not classified as medications. No insurance pathway exists.
For HSA-holders or FSA-holders, the protocol design question often includes which peptides have documentation pathways that permit pre-tax dollars. Compounded GLP-1s during the shortage period had this; the post-2025 landscape is more constrained.
Annual Cost Projections by Protocol
The aggregate annual cost picture for common protocols:
Recovery-focused protocol (BPC-157 + TB-500 + GHK-Cu):
- Telehealth: $9,000–18,000
- Compounding direct: $5,400–11,000
- Gray-market: $2,400–5,500
Hormonal optimization protocol (sermorelin/ipamorelin + PT-141 situational):
- Telehealth: $5,000–9,500
- Compounding direct: $3,100–6,000
- Gray-market: $1,400–2,800
GLP-1 weight loss protocol (branded Wegovy or Zepbound + body composition support):
- Insured with prior authorization: $300–1,800 annual copays
- Cash-pay branded: $12,700–17,000
- Gray-market: $1,200–3,500
Comprehensive longevity stack (recovery + hormonal + cognition + GLP-1 + mitochondrial):
- Telehealth: $25,000–45,000
- Compounding direct: $14,000–28,000
- Gray-market: $5,500–13,000
The longevity extension protocol, recovery stack, and TRT support protocol cover the framework for which interventions go in which stack; the cost is what determines feasibility.
Notable Telehealth Clinic Comparison
The major telehealth clinics in 2026 and their relative positioning:
Hone Health: hormone-focused clinic with peptide options. Pricing typical for the segment. Strong on testosterone optimization integration. The hormonal panels they run map well to the free testosterone and total testosterone targets, hsCRP, and vitamin D baselines that inform protocol design.
Marek Health: similar profile to Hone, with more emphasis on broader optimization protocols. Higher price point on average. Maps to the longevity extension protocol framework.
Eden: telehealth GLP-1 focus, expanded into broader peptide offerings. Lower price point in the segment. Insurance integration limited.
Henry Meds / Mochi: focused on GLP-1s; expanded offerings post-compounding shutdown. Pricing has risen substantially as compounded supply contracted.
Push Health: generalist telehealth with peptide options. Lower price point but more limited consultation depth.
The choice between clinics depends on protocol complexity, integration with broader hormonal or longevity work, and price sensitivity.
The Protocol
- Map your protocol before pricing channels. Decide what peptides at what doses serve your goal. The protocols framework helps define the protocol; pricing flows from the design rather than the other way around.
- Cost the protocol across all three channels. Telehealth, compounding direct, gray-market. The 3–8x range between channels is large enough that channel selection matters more than peptide selection for many users.
- For FDA-approved peptide drugs, run the insurance pathway first. Wegovy, Zepbound, Ozempic, Mounjaro have insurance pathways that can reduce effective cost from $1,000+/month to $25–150/month. Branded with insurance often beats compounded cash-pay.
- For HSA/FSA holders, document everything. Letter of Medical Necessity from prescriber, prescription, pharmacy receipts. The reimbursement is real money — peptides at $200–400/month with HSA reimbursement at marginal tax rate equate to $140–300/month effective cost.
- Consider compounding pharmacy direct if you have an established prescriber. The 30–60% savings vs telehealth-equivalent are meaningful at multi-thousand-dollar annual protocols.
- For gray-market sourcing, treat supplier diligence as the primary quality control. See the reconstitution practical guide for handling protocols and the peptide legality picture for the legal context.
- Avoid stacking beyond what you can sustain financially. A peptide protocol that runs $1,500/month is not effective if budget pressure forces discontinuation at month 3. Sustainable protocol is better than maximalist protocol.
- Track biomarker response, not just subjective response. Total testosterone, hsCRP, HRV, VO2 max — biomarker changes justify cost. Subjective response alone produces protocol drift.
- Reassess pricing every 6 months. The regulatory landscape continues to shift. The 2025 GLP-1 shutdown was not the last consequential pricing event in the peptide market.
- Build a written protocol with cost projections before committing. A $300/month protocol that runs 18 months is a $5,400 commitment. Treat it as the capital allocation it is.
Key Takeaways
- Peptide pricing varies 3–8x across telehealth clinics, compounding pharmacies, and gray-market research chemical sources — channel selection matters more than peptide selection for many users.
- The 2025 GLP-1 compounding shutdown ended the era of $199–299 compounded semaglutide; branded products at $1,000–1,400/month with insurance prior authorization are the practical pathway for most US patients in 2026.
- FDA-approved peptide drugs are HSA/FSA eligible and insurance-coverable; compounded peptides are sometimes HSA/FSA eligible with documentation; research chemicals are never reimbursable.
- BPC-157 monthly cost ranges $80–450 by channel; sermorelin $60–500; GHK-Cu $40–350; PT-141 situational use $40–250/month — annual budgets for full stacks range $2,400–45,000.
- Telehealth clinics charge 50–150% markup over compounding pharmacy direct; the markup covers physician oversight and is reasonable for some users but not for those with established prescribing relationships.
Want a personalized peptide protocol with cost projections mapped to your channel preferences and goals? → Take the PrimalPrime Assessment to map peptide selection, dosing, and biomarker tracking to your profile.